8 results
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
2 Oct 23
Prospectus supplement for primary offering
5:10pm
and/or produce significant reputational, financial, legal, regulatory, business or operational harm. For example, any loss of clinical trial data for our
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
28 Sep 23
Prospectus supplement for primary offering
4:01pm
result in a material disruption of our operations or development programs and/or produce significant reputational, financial, legal, regulatory, business
- Prev
- 1
- Next